pH-Sensitive Anticancer Prodrugs for Tumor-Selective Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing chemotherapies face challenges in selectively delivering anticancer drugs to tumors while minimizing exposure to healthy tissues, leading to high side effects and a narrow therapeutic index.
Innovation Solution
Development of compounds with a core acid covalently bonded to an anticancer drug through a linker, designed to be stable in the bloodstream and selectively release the drug within the acidic tumor microenvironment, enhancing tumor-specific delivery and reducing healthy tissue exposure.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chemotherapies are administered, then anticancer drugs can reach tumor tissues, but healthy tissues are also exposed leading to high side effects
Solution Approach 1:
The patent modifies the chemical structure of anticancer drugs by attaching a carboxylic acid group with a specific pKa range (4.5-7.5) to create pH-sensitive prodrugs. This parameter change enables the drug to exist in different ionization states at different pH levels, allowing selective accumulation in acidic tumor microenvironments (pH 6.0-6.5) while remaining ionized and excluded from neutral pH healthy tissues (pH 7.4)
Solution Approach 2:
The patent introduces a pH-sensitive carboxylic acid group as an intermediary element between the drug molecule and the tumor microenvironment. This intermediary exploits the pH difference between tumors and healthy tissues to mediate selective drug delivery, acting as a molecular gatekeeper that controls drug distribution based on local pH conditions
2Reliability
If chemotherapeutic drugs are delivered systemically, then tumors can be treated, but selective delivery to tumors versus normal tissues is poor
Solution Approach 1:
The patent exploits the pH parameter difference between tumor microenvironments and healthy tissues to achieve selective delivery. By designing prodrugs with carboxylic acid groups having pKa values between 4.5-7.5, the drugs become protonated in acidic tumors (enhancing membrane permeability and accumulation) while remaining deprotonated in neutral healthy tissues (reducing uptake), thereby achieving precise spatial selectivity without complex targeting mechanisms
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds exhibit enhanced accumulation and activity in tumors, improving therapeutic efficacy while minimizing side effects in healthy tissues, thus widening the therapeutic index.
Implementation Method 1
These pH values are known to influence the ionization state of weak ions. Although healthy tissues have a slightly basic pH of 7.4, tumors commonly produce a bulk acidic extracellular pH below pH 7, and the pH at cell surfaces is even lower than the bulk extracellular pH values
Data Source
AI summary
The present invention provides drug modifications for improving biodistribution and/or specificity of an anticancer drug. In certain embodiments, the compound of the invention comprises a drug, a linker and a core acid. The core acid can be varied to tune the properties of the compound within the body such that the compound more selectively distributes to tumors and is, or becomes active in the cytosol.